Imunon Inc IMNN announces interim progression-free survival (PFS) and overall survival (OS) data with IMNN-001 in its Phase 1/2 OVATION 2 Study of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) for newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Interim data from the intent-to-treat (ITT) population demonstrated a delay in disease progression in the treatment arm of approximately 33% compared with the control arm.
Preliminary OS data follows a similar trend, showing an approximate 9-month improvement in the treatment arm over the control arm.
Subgroup analyses show that patients treated with a PARP inhibitor (PARPi) as maintenance therapy had longer PFS and OS if they were also treated with IMNN-001 than patients treated with NACT only.
The median PFS in the PARPi + NACT group and the PARPi + NACT + IMNN-001 group was 15.7 months and 23.7 months, respectively.
The median OS in the PARPi + NACT group was 45.6 months and has not yet been reached in the PARPi + NACT + IMNN-001 group.
IMUNON also sees benefits in other secondary endpoints, including an approximately 20% higher R0 tumor resection score and a doubling of the CRS 3 chemotherapy response score to approximately 30% in the treatment arm versus 14% in the control arm.
Safety analyses continue to show good tolerability of IMNN-001 in this setting.
The final readout of this study is expected by mid-2024.
Price Action: IMNN shares are down 6.62% at $0.95 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
